Table 2.
COVID-19 vaccine candidates in Phase III trials [67].
| Vaccine | Type | Location |
|---|---|---|
| Sinovac | Inactivated virus | Brazil |
| Beijing Institute of Biological Products/Sinopharm | Inactivated virus | China |
| University of Oxford/AstraZeneca | Viral vector | USA |
| Gamaleya Research Institute | Viral vector | Russia |
| Novavax | Protein subunit | The United Kingdom |
| Moderna/NIAID | RNA | USA |
| Medicago Inc | Virus Like Particles | Canada |
| Wuhan Institute of Biological Products/Sinopharm | Inactivated virus | United Arab Emirates |
| Bharat Biotech | Inactivated virus | India |
| CanSino Biological Inc./Beijing Institute of Biotechnology | Viral vector⁎ | Pakistan |
| Janssen Pharmaceutical Companies | Viral vector | USA, Brazil, Colombia, Peru, Mexico, Philippines, South Africa |
| Anhui Zhifei Longcom Biopharma/Institute of Microbiology, Chinese Academy of Sciences | Protein subunit | China |
| BioNTech/Fosun Pharma/Pfizer | RNA | USA, Argentina, Brazil |
⁎
Single dose vaccination (all listed vaccines require two doses).